Celldex Therapeutics (CLDX) 10-K2004 FY Annual report

Filed: 16 Mar 05, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: accrual, adequacy, AdProTech, aforementioned, andSalmonella, annum, APB, blended, budgeted, Cape, categorized, CFO, cholerea, classification, Cod, collateralized, contingent, Cooke, COSO, deposit, deteriorate, disbursement, disposition, distance, doubtful, drawn, easily, encouraged, equal, EquiServe, fermentation, Fifty, holding, Importantly, inadvertent, inCirculation, Inflazyme, infrastructure, inInternal, invoiced, Keilani, LLP, loan, Mexican, Mexico, mid, monthly, Outline, owed, Pacific, paper, pertain, professional, Promissory, pronouncement, ramp, reevaluate, release, reschedule, reset, resetting, revised, rPA, run, Sanofi, stop, supplier, Taha, Timothy, translated, translation, Treadway, undistributed, unrealized, unvested, upfront, USA, voluntarily

Removed: abandoned, additionally, approximated, auditing, breast, cellular, composed, conservative, CTL, cytotoxic, discounting, distinguished, divesting, efficiently, Enterotoxigenic, Esperion, estimating, fight, formation, Henson, indefinite, induce, induced, influenza, Jewish, Karolinska, Langer, Libby, Lyme, Mak, medicine, melanoma, Michigan, minute, Nomura, Ontario, ovarian, PaineWebber, peter, Pharma, potent, producing, prostate, redeem, redeemed, representation, resolution, reviewed, Robert, safely, School, settlement, SMIR, split, Stanford, STTR, sublessee, submit, Tak, thousandth, upside, vivo, ward, Wigzell, write

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

CLDX similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

QuickLinks -- Click here to rapidly navigate through this document

Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in the Registration Statements on Forms S-8, (File Nos. 333-52796, 333-34780, 33-80036, 33-80050, 333-62017, 333-117601 and 333-117602) and the Registration Statements on Forms S-3 (File Nos.] 333-64704, 333-43204, 333-52736, 33-64021, 333-08607, 333-56755, 333-64761, 333-89341, 333-109583 and 333-106918), of AVANT Immunotherapeutics, Inc. (f/k/a TCell Sciences, Inc.) of our report dated March 16, 2005 relating to the financial statements, management's assessment of the effectiveness of internal control over financial reporting and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.

/s/ PricewaterhouseCoopers LLP

PricewaterhouseCoopers LLP
Boston, Massachusetts
March 16, 2005

QuickLinks

Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM